Liver cancer is a serious and often late-diagnosed disease, with hepatocellular carcinoma (HCC) being the most prevalent form, accounting for 90% of cases. HCC typically develops in individuals who have experienced chronic liver damage. Over time, the liver’s natural regenerative processes can result in scarring, inflammation, and ultimately, the development of cancer.
Despite its substantial global impact, liver cancer remains underfunded and insufficiently studied. The LivBC program is committed to bridging this gap by identifying biomarkers linked to the onset and progression of liver cancer, which will contribute to earlier detection and more effective treatment strategies.